PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Translational Radiation Oncology"
DOI: 10.1016/j.ctro.2017.11.003
Abstract: Highlights • The manuscript details the rationale, design and protocol for PARADIGM-2.• PARADIGM-2 comprises two parallel phase I, dose escalation studies of the PARP inhibitor olaparib in combination with radiotherapy (for MGMT unmethylated patients) and… read more here.
Keywords: paradigm; olaparib radiotherapy; radiotherapy; parallel phase ... See more keywords